CStone Pharmaceuticals
29
2
5
20
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 35/100
3.4%
1 terminated/withdrawn out of 29 trials
95.2%
+8.7% vs industry average
21%
6 trials in Phase 3/4
15%
3 of 20 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (29)
A Study of Nofazinlimab (CS1003) in Subjects With Advanced Hepatocellular Carcinoma
Role: lead
A Phase I/II Study of CS2009 in Participants With Advanced Solid Tumors
Role: lead
A Phase I Study of CS5007 in Participants With Advanced Solid Tumors
Role: lead
Study of Sugemalimab (or Placebo) Plus PGemOx Regimen in Participants With Extranodal NK/T-Cell Lymphoma
Role: lead
A Study of Lorlatinib in Subjects With ROS1-Positive Non-Small Cell Lung Cancer
Role: lead
Safety and Efficacy of Avapritinib in Chinese Patients With Gastrointestinal Stromal Tumor (GIST) in the Real World
Role: lead
A Study of CS5001 in Patients With Advanced Solid Tumors and Lymphomas
Role: lead
A Study of CS1001 in Subjects With Stage IV Non-Small Cell Lung Cancer
Role: lead
A Study of CS1002 in Subjects with Advanced Solid Tumors
Role: lead
A Study of CS3006 in Subjects with Locally Advanced or Metastatic Solid Tumors
Role: lead
A Study of CS1001 in Subjects with Advanced Solid Tumors
Role: lead
A Study of CS1001 in Subjects With Relapsed or Refractory Extranodal Natural Killer/ T Cell Lymphoma(ENKTL)
Role: lead
Safety and Tolerability Evaluation of Low-dose Radiation in Combination With CS1001 in Relapsed SCLC Patients
Role: lead
A Study of CS1001 in Subjects With Gastric Adenocarcinoma or Gastro-Esophageal Junction Adenocarcinoma
Role: lead
A Study of CS1001 in Subjects With Esophageal Squamous Cell Carcinoma
Role: lead
A Study of CS1001 in Subjects With Stage III Non-Small Cell Lung Cancer
Role: lead
A Study of CS3007 in Subjects With Gastrointestinal Stromal Tumor
Role: lead
A China Bridging Study of Ivosidenib in r/r AML Subjects With an IDH1 Mutation
Role: lead
A Phase Ib/II Study of Fisogatinib(BLU-554) in Subjects With Hepatocellular Carcinoma
Role: lead
A Study of CS1003 in Subjects With Advanced Solid Tumors or Lymphomas
Role: lead